Healthcare ETF Picks That Could Outperform This Year Show Surprising Tilts
Healthcare ETF picks that could outperform this year
The healthcare ETF most likely to outperform this year is Vanguard Health Care ETF (VHT) if you want broad, low-cost exposure, while Health Care Select Sector SPDR Fund (XLV) is the cleaner blue-chip option and iShares Global Healthcare ETF (IXJ) offers the best case for international diversification as healthcare sentiment improves in 2026. Recent market commentary points to sector inflows, easing policy fears, and an active M&A backdrop as the main catalysts behind the case for a healthcare rebound this year.
Why healthcare now
Healthcare has a classic defensive profile because demand is tied to treatment, aging, and chronic disease rather than the economic cycle, but 2026 also brings a growth overlay from biotech deal activity, digital health, and AI-enabled care delivery. JPMorgan noted in early 2026 that technology-enabled care and digital-first drug development are becoming more central to the sector, while ING projected pharma M&A could accelerate as lower rates and patent cliffs push larger companies to buy growth.
![Mortal Kombat: Special Forces [N64/PSX - Unreleased/Beta] - Unseen64](https://www.unseen64.net/wp-content/uploads/2008/04/mk-special-forces-beta-01.jpg)
That matters for ETF selection because broad funds can benefit from multiple drivers at once: stable drug cash flows, a rebound in medical devices, and selective upside from biotech recovery. BlackRock also highlighted that healthcare ETFs saw their largest monthly global inflows in five years in November 2025, signaling that investors were already rotating back into the space.
Best funds to watch
If the goal is outperforming this year, the strongest healthcare ETF candidates combine low fees, deep holdings, and exposure to the parts of healthcare most likely to benefit from 2026's policy and deal backdrop.
| ETF | Why it stands out | Expense ratio | Key exposure |
|---|---|---|---|
| VHT | Broad, diversified healthcare basket with low costs and strong long-run reputation. | 0.09% | Pharma, biotech, devices, services |
| XLV | Large-cap healthcare leader with high liquidity and concentrated quality exposure. | 0.08% | Big pharma, managed care, devices |
| IXJ | Global diversification can help if U.S. healthcare leadership broadens internationally. | 0.40% | Global pharma, biotech, medtech |
| IBB | Biotech upside if M&A, approvals, and funding conditions improve. | 0.45% | Large-cap biotech |
| XBI | Higher-risk, equal-weight biotech play that can outperform in a strong risk-on biotech tape. | 0.35% | Smaller and mid-cap biotech |
Top picks explained
VHT is the most balanced choice for investors who want a broad healthcare core without paying much for it. Vanguard's fund has a 0.09% expense ratio and very large asset base, which helps keep trading costs and tracking friction low.
XLV is the simplest large-cap healthcare bet and one of the cheapest sector ETFs available, with a 0.08% gross expense ratio and 59 holdings as of May 2026. SSGA's fund data also shows heavy weights in pharmaceuticals, providers, biotechnology, and equipment, which gives it a good mix of stability and upside if the sector keeps recovering.
IXJ is attractive if you think the healthcare rebound will not be limited to the United States. Zacks reported that IXJ had gained 16.3% over the prior year and that global healthcare ETFs saw strong inflows late in 2025, which supports the idea that international exposure may add a tailwind this year.
IBB and XBI are the higher-beta plays. Biotech is more sensitive to FDA decisions, clinical trial data, and takeover activity, but 2026 is shaping up as a better environment because biopharma M&A, licensing, and IPOs already showed renewed momentum in Q1.
What could drive returns
- Lower rates can improve biotech valuations and make acquisitions easier to finance.
- Patent cliffs can force big pharma to buy growth rather than wait for it.
- AI and digital health are improving productivity and narrowing the gap between clinical innovation and operational efficiency.
- GLP-1 obesity drugs continue to reshape demand across chronic care, cardiometabolic treatment, and downstream services.
- Healthcare ETF inflows have improved, which often helps momentum-sensitive subsectors like biotech and medtech.
Most likely winners
The single best pick for a large share of investors is VHT, because it offers the broadest mix of healthcare exposure with nearly the same fee advantage as XLV and a more diversified portfolio. The best tactical upside pick is IBB or XBI if you expect biotech M&A and clinical catalysts to keep improving through the year.
For investors who want to tilt toward quality and cash flow, XLV is a very strong alternative because it concentrates on the biggest and most profitable names in the sector while staying inexpensive. For those who want non-U.S. exposure, IXJ is the cleanest way to play a broader global healthcare recovery.
How to choose
- Pick VHT if you want a core healthcare holding with broad diversification and low fees.
- Pick XLV if you want a more concentrated large-cap portfolio with extremely low costs.
- Pick IXJ if you want global diversification and are comfortable paying more for it.
- Pick IBB or XBI if you believe biotech will lead the sector's next leg higher.
- Size the position as a satellite allocation if you already own broad market funds, because healthcare still carries regulatory and reimbursement risk.
Risks to watch
Healthcare is not risk-free just because it is defensive. Drug pricing policy, reimbursement pressure, failed trials, and political scrutiny can all hit returns quickly, especially in biotech and managed care.
There is also a concentration issue: XLV is heavily weighted toward a small set of mega-cap names, while biotech ETFs can swing hard on single-company news. That is why the best healthcare ETF for outperforming this year depends on whether you prefer stability, global diversification, or higher-octane upside.
"Investors are prioritizing scalable, tech-enabled solutions that can deliver both clinical and economic value," J.P. Morgan said in its 2026 healthcare outlook, a line that captures why healthcare is drawing renewed attention this year.
Everything you need to know about Healthcare Etf Picks That Could Outperform This Year Show Surprising Tilts
Which healthcare ETF is the safest choice?
VHT is the safest broad choice for most investors because it combines diversification, low fees, and exposure across the main healthcare subsectors. XLV is also a strong conservative option, but it is more concentrated in a smaller set of large-cap names.
Which healthcare ETF has the most upside?
IBB and XBI likely have the most upside if biotech sentiment, M&A, and clinical trial results keep improving. That upside comes with much higher volatility than broad healthcare ETFs.
Is healthcare still defensive?
Yes, because people need treatment in good markets and bad markets, but 2026 is notable because healthcare now has both defensive support and growth catalysts. That combination is why the sector is regaining attention after a relatively weak prior stretch.
Should I buy U.S. or global healthcare?
U.S. funds like VHT and XLV are usually the first stop because they are cheaper and more liquid. Global exposure through IXJ makes sense if you want to spread policy and earnings risk across multiple healthcare markets.